FDA clears a Phase III path for Bio­gen’s BACE drug for Alzheimer’s

Bio­gen has tak­en an­oth­er step for­ward in prep­ping a Phase III pro­gram for its BACE drug for Alzheimer’s, with its part­ner Ei­sai not­ing that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland